• 10.26.18

    Would CMS’s Drug Price Transparency Requirement Really Lower Prices?

    On October 15, the Trump Administration’s Centers for Medicare & Medicaid Services (CMS) published a proposed rule that, if finalized, would require prescription drug makers to include prescription drug price information in broadcast advertising.

  • Blue-Capped-Drug-Bottles-on-Conveyor


    The Election’s Impact on Pharma: Preparing for Potential Scenarios

    The 2016 election will have a major impact on both federal and state healthcare policy. To be prepared for all the possibilities, it’s critical to understand the political dynamics that will be in play under each potential scenario—and what they will mean for the life sciences ...



pursuant to New York DR 2-101(f)

© 2024 Manatt, Phelps & Phillips, LLP.

All rights reserved